Articles from Attivare Therapeutics, Inc.

Attivare Therapeutics, Inc. has announced the receipt of a $6.6 million grant from the Gates Foundation, supporting the advancement of a next-generation, long-lasting malaria vaccine, powered by the proprietary ATTimmune bioscaffold platform. This project is focused on providing an affordable, robust, and easily deployable solution for malaria in low- and middle-income countries, where challenges such as limited cold-chain infrastructure often impede vaccine outreach and coverage.

Attivare Therapeutics, Inc., an innovative oncology company focused on the development of its ATTimmune biomaterial scaffold cancer therapies to treat patients across a range of solid and liquid tumors with significant unmet medical needs, today announced it will present preclinical data for its novel ATT-01 and ATT-02 therapeutics in two poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025.

Attivare Therapeutics, Inc., a pre-clinical stage biotechnology company pioneering new treatments for cancer and infectious diseases through its innovative immune-activating scaffold platform, ATTimmune, has named David Sherris, Ph.D. the company’s new President, Chief Executive Officer, and Chairman of the Board.